Pharmacologic cardioversion in recent-onset atrial fibrillation

Early atrial fibrillation can often be converted with a single antiarrhythmic dose, yet the useful question is not simply which drug works best. The decision depends on arrhythmia duration, haemodynamic stability, structural heart disease, comorbidity, and the patient’s ability to complete monitoring and follow-up. For pharmacologic conversion, recent onset is commonly defined as less than 48 hours, while some protocols extend treatment to seven days.

A patient presenting with palpitations, dizziness or breathlessness needs a 12-lead ECG, blood pressure, oxygen saturation and a focused assessment for ischaemia or heart failure. Ask when symptoms began, confirm the earliest documented AF, review prior episodes and medicines, and check electrolytes, renal function and other tests directed by the clinical picture. A recent echocardiogram may reveal ventricular dysfunction or valvular disease that changes drug eligibility.

Tachycardia with hypotension, ongoing ischaemic chest pain, pulmonary oedema, shock or altered mental state is not a pharmacologic problem. Synchronised electrical cardioversion should follow immediately with resuscitation support. In Australia, ambulance activation is 000; emergency departments in Sydney, Melbourne, Brisbane and other cities, as well as regional hospitals, should use the same immediate escalation pathway rather than waiting for a drug effect.

Treatment must also fit Australian systems. The Therapeutic Goods Administration governs marketed medicines, while the Pharmaceutical Benefits Scheme and Medicare rebates influence what patients and services can afford; IV antiarrhythmics are generally supplied through hospitals, whereas oral therapy depends on pharmacy stock and a valid prescription. Distance, shift work and limited local echocardiography or electrophysiology services can alter whether IV or oral conversion is realistic. Public services can arrange interpreters and telehealth follow-up when language or location would otherwise fragment care.

Establishing when conversion is appropriate

First establish whether conversion is appropriate and feasible. Review the ECG for AF with a rapid, slow or irregular ventricular response, conduction disease, ischaemia and QT or QRS prolongation. Inspect for heart failure, recent surgery, sepsis, alcohol excess, thyroid disease, electrolyte disturbance and medication toxicity. Distinguish AF from atrial flutter or another tachyarrhythmia, because a drug may change the atrial rhythm without restoring effective atrial contraction.

Duration controls the thromboembolic strategy as well as the chance of spontaneous or drug-induced conversion. If AF has persisted beyond 24–48 hours, or the onset is uncertain, many Australian protocols require either therapeutic anticoagulation for three weeks beforehand or transoesophageal echocardiography to exclude atrial thrombus, followed by anticoagulation after cardioversion. Transoesophageal imaging is resource dependent, so rural and remote services may need earlier haematology, pharmacy and cardiology coordination.

Structural heart disease is equally important. Flecainide and other class Ic agents should not be used in a patient with significant coronary disease, left ventricular dysfunction, cardiomyopathy, prior ventricular arrhythmia or important conduction disease. A careful history, ECG, echocardiogram and medication review can identify these risks; specialist advice is preferable when uncertainty remains.

Selecting an antiarrhythmic

Flecainide is often the preferred conversion agent for a stable patient with recent-onset AF and no significant structural heart disease. It can be given orally or intravenously, and the choice of route usually follows urgency and the need for monitoring rather than a major difference in efficacy. Before use, check the ECG and weight, screen for ischaemic disease and impaired ventricular function, and review interactions and contraindications. Oral flecainide should be used with food, while IV administration requires continuous ECG monitoring and immediate treatment for bradycardia or ventricular arrhythmia.

Vernakalant is an IV-only alternative for acute conversion in selected patients. It may be considered when flecainide is unsuitable, provided severe aortic stenosis, haemodynamic instability, renal impairment and other contraindications have been excluded. Because it can cause hypotension or bradycardia, treatment belongs in an equipped monitored area. Availability and subsidy should be checked against the current TGA listing and PBS status rather than assumed from overseas guidelines.

Digoxin, beta blockers, diltiazem and verapamil control ventricular rate but do not reliably convert AF to sinus rhythm. Amiodarone can convert AF, but its slow onset and cumulative toxicity make it a poor routine choice for a straightforward early episode; sotalol likewise is not a preferred acute conversion strategy. If conversion is not necessary immediately, rate control with anticoagulation may be appropriate after shared decision-making.

Comparative evidence should be interpreted through patient selection and safety. The Journal of Arrhythmia CRAPS field bet provides a useful companion for weighing efficacy against operational constraints. A drug with a lower response rate may still be the better choice if it avoids structural-heart-disease risk, needs less monitoring or fits a patient who cannot access repeated hospital assessment.

Choosing the route and treatment setting

IV conversion is generally preferred when rapid rhythm restoration is clinically important, the patient is already under observation, or oral treatment is unsuitable. Flecainide or vernakalant should be administered only where continuous ECG monitoring, IV access and resuscitation facilities are available. Record the rhythm before and after treatment, observe for recurrence and watch the patient long enough to detect hypotension, bradycardia, conduction block or a new ventricular arrhythmia.

Oral flecainide is reasonable for a haemodynamically stable patient whose onset and cardiac substrate have been assessed, particularly when an IV attempt is not aligned with goals of care. The first dose should be given under a documented plan rather than as an unsupervised trial at home. Pharmacy access matters in Australia: PBS availability, after-hours dispensing, stock shortages and the patient’s ability to obtain help can determine whether outpatient oral conversion is safe.

Neither route removes the need for a rescue plan. If the drug fails and the patient remains stable, continued rate control, anticoagulation and timely cardiology or electrophysiology review may be safer than repeated drug dosing. In major cities, same-day access to echocardiography and rhythm services may be available; in rural areas, a planned transfer or telehealth bridge should be arranged before discharge. The decision should record why one route was chosen and why another was rejected.

Making discharge safe and reliable

Discharge is appropriate after a clear rhythm outcome and a short observation period tailored to the agent, dose, comorbidity and local policy. Confirm sinus rhythm on ECG, stable blood pressure and heart rate, resolution of ischaemic or heart-failure symptoms, adequate renal function and no concerning adverse drug effect. There is no single observation period that suits every patient, and a brief stay in a busy Sydney or Melbourne emergency department should not be treated as evidence that outpatient follow-up is unnecessary.

Give the patient plain instructions in their preferred language. Explain that palpitations can recur, that a pulse check may be useful but does not replace ECG assessment, and that they should not take another antiarrhythmic dose unless a clinician has specified when and how. Chest pain, severe breathlessness, fainting, sustained dizziness or significant bleeding requires urgent assessment through 000 or the nearest emergency department. A written plan and an involved family member or support person can reduce unsafe repetition of treatment.

If conversion failed, document ongoing AF rather than labelling it converted. Set a rate-control target, decide on anticoagulation, arrange an echocardiogram if not already performed, and book medical or rhythm-specialist review. Check that the general practitioner has the ECG, drug doses, observations and pending results. A discharge summary sent only to the patient may leave the next clinician without the information needed to prevent duplicated conversion attempts.

Patients with a pacemaker, implantable cardioverter-defibrillator or previous transvenous lead extraction need their device history checked when the rhythm changes. Lead or generator complications can be mistaken for AF, and device interrogation may alter management; the journal’s preoperative risk assessment discussion highlights the value of systematic complication review. Record the device clinic, recent interventions and responsible follow-up service, and seek advice before cardioversion if malfunction is possible.

Securing anticoagulation and follow-up

Anticoagulation decisions continue after conversion. If AF lasted more than 24–48 hours or duration is uncertain, continue anticoagulation for at least four weeks after cardioversion, and use longer-term treatment according to thromboembolic risk. For clearly shorter AF, anticoagulation still depends on stroke risk, comorbidity and patient preference. Assess risk with current Australian guidance and CHA2DS2-VASc, then check renal function, bleeding risk, interactions and adherence when selecting a direct oral anticoagulant or warfarin. Apixaban, dabigatran, rivaroxaban and warfarin have different dosing, monitoring and subsidy requirements.

Preventing recurrence is part of discharge. Review blood pressure, sleep apnoea, alcohol intake, weight, smoking, exercise, sleep and medicines that provoke AF; ask about shift work and long-distance driving, both common in Australia, because dehydration, fatigue and disrupted routines may complicate early follow-up. Provide an ECG pathway for palpitations, encourage the patient to keep a simple symptom and pulse diary, and arrange review within a defined interval rather than waiting for another emergency presentation.

Use a one-page discharge plan that records the confirmed AF duration, agent and dose, conversion outcome, anticoagulation decision and duration, observations, follow-up appointment and urgent return triggers. Give the patient a copy, send it to the general practitioner and relevant cardiology service, and make the next review responsible for checking symptoms, rhythm, medication safety and recurrence. A structured handover turns a single conversion into coordinated care after the patient leaves the emergency department.